1. EMA. EMA (EMA/CHMP/EWP/147013/2004 Committee for Medicinal Products for Human Use [CHMP]). Guideline on the role of pharmacokinetics in the development of medicinal products in the paediatric population. 2007.
www.ema.europa.eu/documents/scientific-guideline/guideline-role-pharmacokinetics-development-medicinal-products-paediatric-population_en.pdf
. Accessed 18 Dec 2017.
2. FDA. General Clinical pharmacology considerations for pediatric studies for drugs and biological products, guidance for industry, 2014. Available from:
https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM425885.pdf
.Accessed December 2017
3. Zisowsky J, Krause A, Dingemanse J. Drug development for pediatric populations: regulatory aspects. Pharmaceutics. 2010;2(4):364–88.
4. Krekels EH, Neely M, Panoilia E, Tibboel D, Capparelli E, Danhof M, et al. From pediatric covariate model to semiphysiological function for maturation: part I-extrapolation of a covariate model from morphine to zidovudine. CPT Pharmacometrics Syst Pharmacol. 2012;1:e9.
5. Zhao W, Biran V, Jacqz-Aigrain E. Amikacin maturation model as a marker of renal maturation to predict glomerular filtration rate and vancomycin clearance in neonates. Clin Pharmacokinet. 2013;52(12):1127–34.